Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results